Emulation of a phase 3 study comparing Rituximab with Dimethyl Fumarate in early Relapsing-Remitting Multiple SclerosisFirst published 22/01/2025 Last updated 22/01/2025 EU PAS number: EUPAS1000000450StudyOngoing